Full-year EXPAREL net product sales of $549.0 million in 2024, compared with $538.1 million in 2023. Full-year net product sales were comprised of average daily volume growth of 4 percent. There were 249 selling days in 2024 and 250 selling days in 2023. Full-year ZILRETTA net product sales of $118.1 million in 2024, compared with $111.1 million in 2023. Full-year iovera degrees net product sales of $22.8 million in 2024, compared with $19.7 million in 2023. Other revenue, including sales of bupivacaine liposome injectable suspension and royalties, was $11.1 million in 2024, compared with $6.1 million in 2023.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira announces five-year objectives to accelerate transition
- Pacira reports Q4 EXPAREL net product sales $147.7M vs. $143.9M last year
- Pacira price target raised to $18 from $16 at RBC Capital
- Pacira receives 510k clearance for iovera Smart Tip
- DOMA Perpetual Capital to nominate four candidates to Pacira’s board